A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers

Venous Thromboembolism Clinical Trial

Official title:

A First-in-human, Randomised, Placebo-controlled, Double-blind, Single and Multiple Dose Study to Explore the Safety, Tolerability, PK and PD of Oral Doses of ONO-7684 in Healthy Subjects Under Fed and Fasted Conditions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03919890
• Other study ID #: ONO-7684-01
• Status: Completed
• Phase: Phase 1
• Start date: January 17, 2019
• Est. completion date: August 23, 2019

Study information

• Verified date: December 2019
• Source: Ono Pharmaceutical Co. Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a first in human study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ONO-7684 in healthy adult volunteers. This study will be conducted in 2 parts: Part A is a single-ascending dose and Part B is a multiple-ascending dose.

Description:

This study aims to obtain safety, tolerability, pharmacokinetic and pharmacodynamic data when ONO-7684 is administered orally as single doses and as multiple doses to healthy subjects. The study will consist of 2 parts: A single ascending dose (SAD) phase (Part A); a multiple ascending dose (MAD) phase (Part B). One cohort of Part A will receive ONO-7684 under both fasted and fed conditions to investigate the effect of food.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: August 23, 2019
• Est. primary completion date: August 23, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. 18-55 years

2. normotensive male volunteers, or female volunteers of non-childbearing potential (Part B only)

3. body mass index 18.0-30.0 kg/m2

4. deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine

5. registered with a General Practitioner (GP) in the UK

6. agree to use an effective method of contraception

7. able to give fully informed written consent

Exclusion Criteria:

1. Positive tests for hepatitis B & C, HIV

2. severe adverse reaction to any drug

3. sensitivity to trial medication

4. drug or alcohol abuse

5. current smoker or use of nicotine containing products in the previous 6 months

6. vegetarians or vegans, or unwilling to eat a high-fat breakfast (Part A food effect cohorts only)

7. use of strong CYP3A4/5 or P-glycoprotein inhibitors or inducers, anticoagulants, antiplatelet agents, non-steroidal anti-inflammatory drugs and/or acetylsalicylic acid within the previous 30 days

8. prescription or over-the-counter medication, vitamins, herbal treatments or dietary supplements within the previous 7 days (with the exception of paracetamol [acetaminophen])

9. participation in other clinical trials of unlicensed medicines, or loss of more than 400 mL blood, within the previous 3 months or plan to donate blood or blood products in the 3 months after the trial

10. vital signs outside the acceptable range

11. clinically relevant abnormal findings at the screening assessment (including creatinine clearance, haemoglobin levels and QTcF)

12. acute or chronic illness

13. clinically relevant abnormal medical history or concurrent medical condition

14. objection by GP

15. possibility that volunteer will not cooperate

16. pre-menopausal females who are pregnant or lactating, or who are of childbearing potential

Related Conditions & MeSH terms

• Thromboembolism
• Venous Thromboembolism

Intervention

Drug:
• ONO-7684
Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
• ONO-7684 Placebo
Placebo comparator

Locations

Country	Name	City	State
United Kingdom	Hammersmith Medicines Research (HMR)	London

Sponsors (1)

Lead Sponsor	Collaborator
Ono Pharmaceutical Co. Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with clinically significant changes in vital signs (Part A & B)	Pulse rate (bpm), systolic and diastolic blood pressure (mmHg), Respiratory rate (bpm)	Part A: Day 1-4 & Follow-up and Part B: Day 1-15, 17 & Follow up
Primary	Number of participants with clinically significant changes observed on 12-lead electrocardiogram (ECG) (Part A & B)	Ventricular rate (beats/min), PR interval (msec), QRS interval (msec), QT (msec), QTcF interval (msec)	Part A: Day 1-4 & Follow up & Part B: Day 1,3,5,7,9,11,14,17 & Follow up
Primary	Number of participants with clinically significant changes in cardiac telemetry (Part A only)	Number of participants with cardiac telemetry abnormalities will be reported.	Part A: From 0.5-1 hours pre-dose until 12 hours after dosing at Day 1
Primary	Number of participants with clinically significant changes in physical examination (Part A & B)	Number of participants with physical examination abnormalities will be reported.	Part A: Day -1, 1-4 & Follow-up and Part B: Day-1, 1-17 & Follow up
Primary	Number of participants with clinically significant changes in laboratory safety tests (haematology, biochemistry and urinalysis) (Part A & B)	Number of participants with abnormalities in laboratory safety tests will be reported.	Part A: Day-1, 1-4 & Follow up and Part B: Day-1, 1-17 & Follow up
Primary	Number of participants with adverse events (AE) (Part A & B)	AE is any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.	Part A: Day-1, 1-4 & Follow up and Part B: Day-1, 1-17 & Follow up
Secondary	Pharmacokinetics (Cmax)	Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B	Part A: Day 1 through Day 4. Part B: Day 1 and Day 14
Secondary	Pharmacokinetics (tmax)	Assessment of the maximum observed plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B	Part A: Day 1 through Day 4. Part B: Day 1 and Day 14
Secondary	Pharmacokinetics (AUClast)	Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B	Part A: Day 1 through Day 4. Part B: Day 14
Secondary	Pharmacokinetics (AUCinf)	Assessment of the area under the curve of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B	Part A: Day 1 through Day 4. Part B: Day 14
Secondary	Pharmacokinetics (AUCt)	Assessment of the area under the curve of concentration of ONO-7684 and 3-hydroxybenzoic acid - time from zero up to a definitive time, t in Parts A and B	Part A: Day 1 through Day 4. Part B: Day 1
Secondary	Pharmacokinetics (%AUCextrap)	Assessment of the percentage of AUC8 extrapolated from tlast to infinity of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B	Part A: Day 1 through Day 4. Part B: Day 14
Secondary	Pharmacokinetics (t1/2)	Assessment of the elimination half-time of ONO-7684 and 3-hydroxybenzoic acid in Parts A and B	Part A: Day 1 through Day 4. Part B: Day 14
Secondary	Pharmacokinetics (CL/F)	Assessment of the apparent clearance rate of ONO-7684 and 3-hydroxybenzoic acid in Part A only	Day 1 through Day 4
Secondary	Pharmacokinetics (Terminal Rate Constant)	Assessment of the terminal rate constant (slowest rate constant of the disposition) of ONO-7684 and 3-hydroxybenzoic acid in plasma in Part A only	Day 1 through Day 4
Secondary	Pharmacokinetics (Aet)	Assessment of the amount of ONO-7684 excreted in urine over the period of sample collection in Part A only	Day 1 through Day 4
Secondary	Pharmacokinetic (fe/F)	Assessment of the fraction of orally administered ONO-7684 excreted into urine in Part A only	Day 1 through Day 4
Secondary	Pharmacokinetic (CLr)	Assessment of the renal clearance of ONO-7684 from plasma in Part A only	Day 1 through Day 4
Secondary	Pharmacokinetic (Ctrough)	Assessment of the trough plasma concentration of ONO-7684 and 3-hydroxybenzoic acid in Part B only	Day 1 through Day 14
Secondary	Pharmacokinetic (AUCtau)	Assessment of the area under the plasma concentration of ONO-7684 and 3-hydroxybenzoic acid -time during a dosing interval in Part B only	Day 14
Secondary	Pharmacokinetic (CLSS/F)	Assessment of total clearance of ONO-7684 from plasma after oral administration in Part B only	Day 14
Secondary	Pharmacokinetic (VZ/F)	Assessment of apparent volume of distribution of ONO-7684 after non-intravenous administration calculated at steady state in Part B only	Day 14
Secondary	Pharmacodynamic (change from baseline in aPTT activity) in serum	Assessment of the effect of ONO-7684 in activated partial thromboplastin time in Parts A and B	Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
Secondary	Pharmacodynamic (change from baseline in PT activity) in serum	Assessment of the effect of ONO-7684 in prothrombin time in Parts A and B	Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
Secondary	Pharmacodynamic (change from baseline in PT-INR activity) in serum	Assessment of the effect of ONO-7684 in prothrombin time-international normalised ratio in Parts A and B	Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
Secondary	Pharmacodynamic (change from baseline in FXIa activity) in serum	Assessment of the effect of ONO-7684 in blood coagulation activated factor XI in Parts A and B	Part A: Day 1 through Day 4. Part B: Day 1 through Day 17
Secondary	Pharmacodynamic (correlation of aPTT and FXIa activity) in serum	Assessment of the effect of ONO-7684 in the correlation of activated partial thromboplastin time to blood coagulation activated factor XI in Parts A and B	Part A: Day 1 through Day 4. Part B: Day 1 through Day 17